

N.E. - the epitope contained between aspartic acid 2108 and glycine 2121,
defined by the following sequence:

**Please replace the paragraph on page 17, lines 15 to 19, with the following
rewritten paragraph:**

C2 These characteristics are particularly pronounced in the cases of epitopes SEQ
ID No: 2 and SEQ ID No: 5, which comprise sequences which are relatively "long" in
amino acids, i.e. comprise 16 and 22 amino acids, respectively.

IN THE CLAIMS

Please amend Claims 31, 32, 34-36 and 39 as follows:

31. (Amended) An antigenic polypeptide comprising at least 7 amino acids of a
Factor VIII fragment selected from the group consisting of a Factor VIII fragment
contained between arginine 1652 and arginine 1696 inclusive, a Factor VIII fragment
contained between threonine 1739 and aspartic acid 1831 inclusive, and a Factor VIII
fragment contained between glutamic acid 1885 and arginine 1917 inclusive.

32. (Amended) An antigenic polypeptide according to Claim 31, wherein said Factor
VIII fragment comprises an epitope selected from the group consisting of:

C3 a Factor VIII fragment contained between arginine 1652 and tyrosine 1664 (SEQ
ID No:1), a Factor VIII fragment contained between aspartic acid 1681 and arginine
1696 (SEQ ID No:2), a Factor VIII fragment contained between threonine 1739 and
tyrosine 1748 (SEQ ID No:3), a Factor VIII fragment contained between asparagine
1777 and phenylalanine 1785 (SEQ ID No:4), a Factor VIII fragment contained between
glutamic acid 1794 and tyrosine 1815 (SEQ ID No:5), a Factor VIII fragment contained
between methionine 1823 and aspartic acid 1831 (SEQ ID No:6), a Factor VIII fragment
contained between glutamic acid 1885 and phenylalanine 1891 (SEQ ID No:7), a
Factor VIII fragment contained between glutamic acid 1893 and alanine 1901 (SEQ ID
No:8), and a Factor VIII fragment contained between aspartic acid 1909 and arginine
1917 (SEQ ID No:9).

Appl. : 08/765,837
Filed: : September 7, 1999

33. **(Amended)** An antigenic polypeptide according to Claim 31, wherein said antigenic polypeptide comprises tyrosine or histidine.

C3
34. **(Amended)** A conformational epitope containing at least two different epitopes of the antigenic polypeptide of Claim 32.

①
35. **(Amended)** A conformational epitope containing at least two different epitopes from a Factor VIII fragment selected from the group consisting of a Factor VIII fragment contained between arginine 1652 and arginine 1696 inclusive, a Factor VIII fragment contained between threonine 1739 and aspartic acid 1831, inclusive, and a Factor VIII fragment contained between glutamic acid 1885 and arginine 1917 inclusive.

36. **(Amended)** A complex comprising a carrier protein or a carrier peptide linked to the antigenic polypeptide of Claim 31 or the conformational epitope of Claim 35.

C4
39. **(Twice Amended)** A pharmaceutical composition comprising at least the antigenic polypeptide of Claim 31, or the conformational epitope of Claim 35 and an acceptable pharmaceutical vehicle.

REMARKS

The specification has been amended to correct minor informalities and to recite that the present application is the U.S. National Phase of PCT/BE95/00068, which claims priority to Belgian application BE 9400666, filed July 14, 1994. These priorities were claimed in the Declaration submitted to the United States Patent and Trademark Office on October 7, 1997. Additionally, the specification has been amended to specify that the location of the amino acids of SEQ ID NO: 19 is from positions 2108-2121. Support for this amendment is found in the specification of WO 96/02572 (published in French) on page 34, lines 18 to 19, from which the present application is the U.S. National Phase. For the Examiner's convenience, Applicants have attached page 34 from WO 96/02572.